Element Materials Technology (Element) has launched a global offering for its Extractables and Leachables (E&L) services.
The new service brings together capabilities across Europe and North America through the recent acquisitions of Avomeen, Hall Analytical and VR Analytical totalling over 75 experts across laboratories in Ann Arbour and Bend in the US, Toronto in Canada and Manchester in the UK.
Regulatory agencies are requiring more and increasingly complex E&L studies before drugs and products come to market. The impact of extractable and leachable substances on product safety and drug product interaction is now studied and evaluated throughout the drug development process to make sure certain drug efficacy and patient safety are not compromised.
Sarah Brophy, global scientific director for extractables and leachables, life sciences, Element, said: “Our combined knowledge and experience helps us deliver an unequalled expertise in the rigorous testing for E&L on a whole range of products across the world’s regulatory authorities. Keeping up with ever increasing demands for product testing and delivery is a significant part of the approval process.”